Encorafenib
About
Therapy type: Targeted therapy
Therapy strategy: B-RAF inhibition
Mappings
NCI Thesaurus: Encorafenib (coding:ncit:C98283)
RxNorm: encorafenib (coding:rxcui:2049106, coding:omop:36674339)
SNOMED: Encorafenib (coding:sctid:772201002, coding:omop:1559914)
Therapeutic response
Precision oncology relationships for therapeutic response involving this therapy.
| Organizations | Biomarkers | Cancer types | Therapies | |
|---|---|---|---|---|
| FDA (2) HC (2) | BRAF p.V600E | Melanoma | Binimetinib, Encorafenib | |
| FDA (2) HC (1) | BRAF p.V600K | Melanoma | Binimetinib, Encorafenib | |
| FDA (2) | BRAF p.V600E | Non-Small Cell Lung Cancer | Binimetinib, Encorafenib | |
| FDA (2) HC (1) | BRAF p.V600E | Colorectal Adenocarcinoma | Cetuximab, Encorafenib | |
| FDA (1) HC (1) | BRAF p.V600E | Colorectal Adenocarcinoma | Cetuximab, Encorafenib, Fluorouracil, Oxaliplatin | |
| FDA (1) | BRAF p.V600E | Colorectal Adenocarcinoma | Cetuximab, Encorafenib, Fluorouracil, Irinotecan |